Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.
2025 · 2nd Quarter (Apr 1 - June 30)
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
Filed by DLA PIPER LLP (US).
Open official filingSource-reported fields
Filing overview
- Type
- 2nd Quarter - Report
- Posted
- Jul 21, 2025
- Income
- $60,000.00
- Expenses
- Not reported
- Registrant
- DLA PIPER LLP (US)
- Filing UUID
- f02f8423-92c6-4d99-9425-3a2e2828cb6c
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
S. 832, EPIC Act of 2025.
Literal federal measure citations: S. 832
Medicare policies.
H.R. 1, One Big Beautiful Bill Act, provisions impacting pharmaceuticals.
Literal federal measure citations: H.R. 1
National security issues related to pharmaceutical industry, including supply chain.
Trade policies and agreements, including IP protections, and administrative tariff actions.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.